Drugs / DLQ01
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05636904 | Dec 2022 → Mar 2024 | androgenetic alopecia | Dermaliq Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DLQ01 | “The goal of this study is to measure the safety, tolerability, and the hair growth response to topical DLQ01 solutions in comparison to the vehicle and a comparator solution in...” NCT05636904 ↗ |
| Route | Topical | “Topical treatment for 24 weeks” NCT05636904 ↗ |